Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
04/26/2023 - 07:00 AM
WALTHAM, Mass. --(BUSINESS WIRE)--
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its first quarter 2023 financial results on Wednesday, May 3, 2023 .
In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Wednesday, May 3, 2023 , to discuss the Company’s financial results and provide a corporate update.
The conference call may be accessed via this link: https://register.vevent.com/register/BI75fb53c225a648b486e50d922b166468
A live webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations . A replay will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.
About Deciphera Pharmaceuticals
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia , Canada , China , the European Union , Hong Kong , Israel , Macau , New Zealand , Switzerland , Taiwan , the United Kingdom , and the United States . For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).
View source version on businesswire.com : https://www.businesswire.com/news/home/20230426005051/en/
Investor Relations:
Maghan Meyers
Argot Partners
Deciphera@argotpartners.com
212-600-1902
Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902
Source: Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals Inc
DCPH Rankings
#4207 Ranked by Stock Gains
DCPH Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Waltham
About DCPH
deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.